Literature DB >> 8530146

Tolerance to lipopolysaccharide in human blood monocytes.

H W Ziegler-Heitbrock1, M Frankenberger, A Wedel.   

Abstract

When monocytes are stimulated with Lipopolysaccharide (LPS), they efficiently produce cytokines like tumor necrosis factor (TNF). Upon secondary stimulation, this response is only minimal, and there is little TNF mRNA transcription, mRNA accumulation, and protein production. Studies with the monocytic cell line Mono Mac 6 have shown that in such tolerant cells the CD14 LPS receptor is still present, and the transcription factor NF-kB is still efficiently mobilized. This NF-kB complex has, however, a different composition, that does not transactivate TNF promoter reportergene constructs. We now show that similar mechanisms apply to primary blood monocytes. After primary stimulation these cells also produce high levels of TNF and then develop tolerance in that upon secondary challenge little TNF is produced. CD14 cell surface expression is unchanged or even increased in tolerant cells and NF-kB mobilization does still occur. The complex mobilized in such tolerant monocytes is, however, composed mainly of high mobility binding proteins. This indicates that p50 homodimers predominate in NF-kB complex of tolerant blood monocytes, similar to what has been reported for Mono Mac 6 cells. The data add to the notion that p50 binding to the cognate -kB DNA motif in the TNF promoter may be responsible for the unresponsiveness in LPS tolerance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530146     DOI: 10.1016/s0171-2985(11)80546-2

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  8 in total

1.  Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis.

Authors:  Laura Brudecki; Donald A Ferguson; Deling Yin; Gene D Lesage; Charles E McCall; Mohamed El Gazzar
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation.

Authors:  Xin Tong; Lei Yin; Raymond Washington; Daniel W Rosenberg; Charles Giardina
Journal:  Mol Cell Biochem       Date:  2004-10       Impact factor: 3.396

3.  NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression.

Authors:  S Kastenbauer; H W Ziegler-Heitbrock
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

Review 4.  MicroRNA in TLR signaling and endotoxin tolerance.

Authors:  Md A Nahid; Minoru Satoh; Edward Kl Chan
Journal:  Cell Mol Immunol       Date:  2011-08-08       Impact factor: 11.530

5.  Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14.

Authors:  M O Labéta; K Vidal; J E Nores; M Arias; N Vita; B P Morgan; J C Guillemot; D Loyaux; P Ferrara; D Schmid; M Affolter; L K Borysiewicz; A Donnet-Hughes; E J Schiffrin
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

6.  High-Density Lipoprotein Reduction Differentially Modulates to Classical and Nonclassical Monocyte Subpopulations in Metabolic Syndrome Patients and in LPS-Stimulated Primary Human Monocytes In Vitro.

Authors:  Johanna L Grün; Aaron N Manjarrez-Reyna; Angélica Y Gómez-Arauz; Sonia Leon-Cabrera; Felix Rückert; José M Fragoso; Nallely Bueno-Hernández; Sergio Islas-Andrade; Guillermo Meléndez-Mier; Galileo Escobedo
Journal:  J Immunol Res       Date:  2018-04-03       Impact factor: 4.818

7.  TLR-dependent cross talk between human Kupffer cells and NK cells.

Authors:  Zhengkun Tu; Adel Bozorgzadeh; Robert H Pierce; Jonathan Kurtis; I Nicholas Crispe; Mark S Orloff
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

8.  Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population.

Authors:  Pengchao Li; Jinbao Gu; Xiao Yang; Hongzhou Cai; Jun Tao; Xuejian Yang; Qiang Lu; Zengjun Wang; Changjun Yin; Min Gu
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.